Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: Benefits versus risks

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 5, 2009, Pages 481-496

  Rostom, A ^a   Moayyedi, P ^b   Hunt, R ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ALGORITHM; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COLORECTAL ADENOMA; COLORECTAL CANCER; CONSTIPATION; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ESOPHAGUS CANCER; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEART INFARCTION; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; INTESTINAL BLEEDING; INTESTINE ULCER; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NAUSEA; PAIN; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STOMACH CANCER; STROKE; UPPER GASTROINTESTINAL BLEEDING; UPPER GASTROINTESTINAL TRACT;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CANADA; CARDIOVASCULAR DISEASES; CONSENSUS; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TIME FACTORS;

EID: 59149099329     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03905.x     Document Type: Review

References (104)

1. Barnard L, Lavoie D, Lajeunesse N. Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern. Drug Saf 2006 29 : 613 20.
2. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 343 : 769 72.
3. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000 321 : 1183 7.
4. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006 131 : 1674 82.
5. Lanas A, Baron JA, Sandler RS, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007 132 : 490 7.
6. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007 5 : 818 28.
7. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 2006 332 : 1302 8.
8. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 296 : 1633 44.
9. Health Canada. Advisory: Health Canada Endorsed Important Safety Information on Celebrex (celecoxib), 2005. Available at: http://www.hc-sc.gc.ca/ ahc-asc/media/advisories-avis/-2005/2005-17-eng.php. (Accessed on 10 December 2008).
10. Food and Drug Administration (FDA). FDA Public Health Advisory: FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-selective Non-steroidal Anti-inflammatory Drugs (NSAIDs). FDA, 2005. Available at: http://www.fda.gov/cder/drug/advisory/COX2.htm. (Accessed on 10 December 2008).
11. Health Canada. Advisory: Withdrawal of Market Authorization for Prexige. Health Canada, 2007. Available at: http://www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/2007/2007-141-e.html. (Accessed on 10 December 2008).
12. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006 33 : 140 57.
13. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs. An Update for Clinicians. A Scientific Statement from the American Heart Association. Circulation 2007 115 : 1634 42.
14. Wilcox CM, Allison J, Benzuly K, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006 4 : 1082 9.
15. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004 19 : 197 208.
16. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008 118 : 1894 909.
17. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008 103 : 2908 18.
18. Lomas J. Words without action? The production, dissemination, and impact of consensus recommendations Annu Rev Public Health 1991 12 : 41 65.
19. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004 328 : 1490.
20. Hayward RS, Wilson MC, Tunis SR, et al. More informative abstracts of articles describing clinical practice guidelines. Ann Intern Med 1993 118 : 731 7.
21. Giacomini M, Cook D, Streiner D, Anand S. Using practice guidelines to allocate medical technologies. An ethics framework. Int J Technol Assess Health Care 2000 16 : 987 1002.
22. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 353 : 2373 83.
23. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002 162 : 2197 202.
24. Tanser P. 2000 revision of the Canadian Cardiovascular Society 1997 Consensus Conference on the Evaluation and Management of Chronic Ischemic Heart Disease. Can J Cardiol 2000 16 : 1513 36.
25. Smith SC Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006 47 : 2130 9.
26. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006 98 : 746 50.
27. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006 295 : 306 13.
28. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 136 : 161 72.
29. Khan NA, McAlister FA, Rabkin SW, et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2006 22 : 583 93.
30. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002 106 : 388 91.
31. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002 94 : 252 66.
32. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001 1 : 11 21.
33. Futagami S, Suzuki K, Hiratsuka T, et al. Chemopreventive effect of celecoxib in gastric cancer. Inflammopharmacology 2007 15 : 1 4.
34. Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003 95 : 1784 91.
35. Dube C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive services task force. Ann Intern Med 2007 146 : 365 75.
36. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007 146 : 376 89.
37. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003 124 : 47 56.
38. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000 57 : 326 32.
39. Lip GY, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 2004 3 : CD003186.
40. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998 280 : 1930 5.
41. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004 75 : 40 7.
42. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006 119 : 624 38.
43. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991 115 : 787 96.
44. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006 55 : 1731 8.
45. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006 24 : 751 67.
46. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006 368 : 1771 81.
47. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003 124 : 288 92.
48. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006 355 : 873 84.
49. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006 355 : 885 95.
50. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 284 : 1247 55.
51. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 364 : 665 74.
52. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006 119 : 255 66.
53. Goldstein JL, Eisen GM, Agrawal N, et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 2004 20 : 527 38.
54. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007 369 : 465 73.
55. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005 352 : 238 44.
56. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006 4 : 860 5.
57. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
58. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 366 : 1607 21.
59. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 354 : 1706 17.
60. Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med 2006 354 : 1744 6.
61. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997 24 : 2 17.
62. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002 359 : 14 22.
63. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006 4 : 130 42.
64. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002 123 : 1006 12.
65. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 123 : 241 9.
66. Laine L, Curtis S, Cryer B, Zhang Y, Cannon C. Risk factors for NSAID-associated upper GI clinical events in a long-term double-blind study of 34,701 arthritis patients [abstract]. Gastroenterology 2007 132 (Suppl. S2 86.
67. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004 127 : 1038 43.
68. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2007 27 : 31 40.
69. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993 35 : 219 26.
70. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003 48 : 12 20.
71. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004 109 : 1468 71.
72. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004 364 : 2021 9.
73. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006 27 : 1657 63.
74. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999 107 : 65S 70S.
75. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006 296 : 1619 32.
76. Stichtenoth DO, Marhauer V, Tsikas D, Gutzki FM, Frolich JC. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 2005 68 : 2197 207.
77. Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Ther 2004 11 : 124 9.
78. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001 281 : F1 11.
79. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 2006 164 : 881 9.
80. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002 25 : 537 44.
81. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002 4 : CD002296.
82. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001 344 : 967 73.
83. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002 347 : 2104 10.
84. Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005 118 : 1271 8.
85. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006 101 : 701 10.
86. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007 369 : 1621 6.
87. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998 338 : 727 34.
88. Wilson DE. Antisecretory and mucosal protective actions of misoprostol. Potential role in the treatment of peptic ulcer disease. Am J Med 1987 83 : 2 8.
89. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998 338 : 719 26.
90. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002 162 : 169 75.
91. Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004 329 : 948.
92. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005 21 : 1411 8.
93. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002 51 : 329 35.
94. Pilotto A, Di Mario F, Franceschi M, et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000 14 : 1077 82.
95. Lai KC, Lam SK, Chu KM, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users - a randomized trial. Aliment Pharmacol Ther 2003 18 : 829 36.
96. Hunt R, Fallone C, Veldhuyzan van Zanten S, et al. Canadian Helicobacter Study Group Consensus Conference: update on the management of Helicobacter pylori- an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 2004 18 : 547 54.
97. Veldhuyzen van Zanten SJ, Bradette M, Chiba N, et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 2005 19 : 285 303.
98. Veldhuyzen van Zanten SJ, Pollak PT, Best LM, Bezanson GS, Marrie T. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994 169 : 434 7.
99. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002 346 : 2033 8.
100. Giral A, Ozdogan O, Celikel CA, et al. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. J Gastroenterol Hepatol 2004 19 : 773 7.
101. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001 52 : 185 92.
102. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003 49 : 283 92.
103. El-Serag HB, Graham DY, Richardson P, Inadomi JM. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med 2002 162 : 2105 10.
104. Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005 53 : 185 97.